Oral herbal supplement containing magnesium sulfate improve metabolic control and insulin resistance in non-diabetic overweight patients: A randomized double blind clinical trial

Mehrdad Solati¹, Leila Kazemi², Naghi Shahabi Majd³, Mansoor Keshavarz², Nima Pouладian⁴, Nepton Soltani*⁵

Received: 12 Mar 2017 Published: 6 Feb 2019

Abstract

**Background:** Magnesium deficiency plays a key role in obesity and decreases insulin sensitivity. In our previous study, significant evidence was provided for the contribution of oral Mg supplement that could improve insulin sensitivity and body weight in animal trials. The purpose of the present study was to investigate the effects of an herbal supplement containing 300 mg magnesium sulfate on lipid profile, as well as insulin resistance and secretion in overweight patients.

**Methods:** Seventy overweight non-diabetic volunteers with Body Mass Index (BMI) >28 kg/m² were included in a randomized double blind placebo-controlled clinical trial (ethical number HUM REC.1394.57) and registered in Iranian Registry of Clinical Trials (IRCT20121101247562 with registration number 24756). They received either placebo or an herbal supplement capsule containing 300 mg magnesium sulfate (MgSO₄) for 6 months on a daily basis. Metabolic control, lipid profile and magnesium status were determined at baseline and every three months. Student t-test, repeated measure ANOVA and ANCOVA were used to compare the groups.

**Results:** There was no significant difference between groups before intervention, but daily Mg supplement for 6 months significantly improved fasting insulin level (6.71±0.11 to 6.27±0.3 three months after Mg therapy, p<0.01 vs. 6.41±0.11 in control group (5.83±0.063) six months after Mg therapy, p<0.0001), HOMA-IR (1.52±0.03) in control group to 1.36±0.03 after three months Mg therapy, p=0.05 vs 1.37±0.05 in control group to 1.22±0.02 six months after Mg therapy (p=0.05), high density lipoprotein cholesterol (HDL) (43.57±0.82 in control group to 43.91±1.92 three months after Mg therapy, p<0.001 vs 43.57±0.82 in control group to 46±0.88 six months after Mg therapy, <0.01), triglyceride (TG) (163.17±6.1 in control group to 141.2±5.84 six months after g therapy, p<0.05) and low density lipoprotein cholesterol (LDL) (112.62±3.41 in control group to 104.42±2.35 six months after Mg therapy, p<0.05).

**Conclusion:** Oral herbal supplement containing MgSO₄ (300 mg/day) could improve plasma insulin level, lipid profile, and insulin resistance in non-diabetic overweight volunteers.

Keywords: Magnesium, Overweight, Blood glucose, Lipid profile, Insulin resistance

**Conflicts of Interest:** None declared

**Funding:** Deputy of Research of Hormozgan University of Medical Sciences

*This work has been published under CC BY-NC-SA 1.0 license.

Copyright © Iran University of Medical Sciences


**Introduction**

Obesity and type 2 diabetes are interrelated. The major foundation for this relationship is the capacity of fatness which stimulates insulin resistance as an essential facet of type 2 diabetes etiology and ties up to an extensive array of other abnormal outcomes including hypertension, hyperlipidemia, atherosclerosis and polycystic ovarian disease (1). Insulin resistance has been shown to impair glucose uptake in type 2 or non-insulin dependent diabetes

¹What is “already known” in this topic:
For improve insulin sensitivity and lipid profiles in non-diabetic insulin resistance patients administration of MgSO₄ can be useful.

→What this article adds:
Mg shortage has been related with insulin resistance and amplified possibility for type 2 diabetes and fatty liver in adults, so herbal supplement containing MgSO₄ administration can be recommended.
mellitus (NIDDM) patients (2). The prevalence of overweight between urban population aged above 18 year and under age 18 year is roughly estimated at 21.7% and 6.1%, respectively (3).

The influence of body fat distribution on insulin sensitivity has been a question of great interest in the literature due to the higher risk of cardiovascular illness and type 2 diabetes in patients, but the exact mediators remain unclear. Magnesium deficiency is said to play a role (4), since it often coincides with insulin resistance in diabetic patients (4). Guerrero-Romero et al showed that a 3-month MgCl₂ (2.5 g daily) therapy could enhance beta cells’ ability to set off insulin sensitivity in non-diabetic patients with considerable hypomagnesaemia (4). Some researchers (4-6) have provided important data indicating that oral Mg supplement improves insulin sensitivity even in overweight, non-diabetic and normal magnesium subjects. They emphasize that early optimization of Mg is necessary to prevent insulin resistance and type 2 diabetes. Kim et al. showed an opposite relationship between magnesium ingestion and diabetes in American new generation. This may be due to the reverse correlation of magnesium intake with systemic inflammation and insulin resistance (7).

In our previous study, we reported that oral magnesium sulfate administration in animal diabetic model could not increase insulin secretion, but could improve insulin sensitivity by an increase in Glucose transporter number 4 (GLUT4) gene expressions (8). It could also correct blood glucose and lipid profile, and lessen high blood pressure and diabetic vascular complications (9-12). We also found that daily administration of 300 mg magnesium sulfate for 3 months in type 2 diabetic patients, significantly improved fasting blood sugar, 2-hour post prandial glucose, lipid profile, blood pressure, and hepatic enzymes (13). In this study however, due to prevalence of overweight among Iranian population, we used an herbal supplement containing MgSO₄ in the non-diabetic obese to measure the efficacy of the drug on insulin resistance.

### Methods

This study was a randomized, double-blind, placebo-controlled trial confirmed by the ethics committee of Hormozgan university of medical sciences (ethic number HUMS REC.1394.5 7) and registered in Iranian Registry of Clinical Trials (IRCT2012110124756N2 with registration number 24756). Data privacy and confidentiality were protected accordingly. All participants and researchers except for two, with randomized participation, were blind to the study protocol. Our colleague who was responsible for sample randomization allocated the participant between groups by using table of random numbers and replacement sample in case if we lost someone. The research flows illustration is presented in Fig. 1.

### Participants

In this study, based on Iranian insulin resistance biomarker and the biostatistician suggestion, the sample size was determined using the following formula:

\[ n = \frac{2SD (z_{α/2}+Z_β)^2}{d^2} \]

(z_{α/2}=1.96, Z_β=0.84)

The inclusion criteria for the overweight volunteers were age (19–69 years), Body Mass Index (>28 kg/m²) (14), adequate cardiovascular and gastrointestinal function and appropriate mobility as well as being non-diabetic, non-pregnant, nortomensive and with no dietary restrictions (our patients followed the usual diet, but we asked them to complete the 24 hours food recall form which we prepared for them) or allergies with no history of food allergy or sensitivity to magnesium supplements. Patients who had known kidney diseases (serum creatinin above 1.3 mg/dl in women and higher than 1.5 mg/dl in men), raised hepatic enzymes (above 3 folds over normal range), current infections (fewer one month during the study) and chronic inflammatory diseases, cerebrovascular accident (CVA) and acute coronary syndrome (ACS) less than a month during the study, but alcoholics or drug users were omitted. Moreover, patients with insulin, calcium channel blockers and Mg supplements were also excluded from the study. After an opening screening and face-off

---

**Fig. 1.** Study follow diagram

---

2 [http://mjr.jums.ac.ir](http://mjr.jums.ac.ir)

period, participants were randomly chosen and enrolled for the study protocol upon taking informed written consent to get either herbal supplement capsules containing 300 mg MgSO$_4$ or placebo (wheat bran) every morning for 6 months (Fig. 1). Six participants did not complete the whole study while other participants followed the usual diet and physical activity during the course of study.

Participants were visited by an endocrinologist blind to the grouping on a weekly basis. Every 3 months blood sample was taken to measure biomedical markers. Patients and staffs were also unsighted to the group management. The study predictor had access to the data and followed the no-contact rule with the participants during the study.

**Study outcomes**
The primary outcome regarding fasting blood glucose concentration and HOMA-IR, measured before intervention and in three-month intervals following the intervention. The secondary outcome related to insulin and lipid profile was also measured in aforementioned times.

**Measurements**
Height and weight were measured with light indoor clothing without shoes, using standard protocols. BMI was calculated through weight in kilograms divided by height in square meters (15).

Fasting blood glucose (FBG) was determined every three months using glucose–oxidase method (Glucose-monoreagent kit, Kimia Pajouhoun, Iran). Moreover, enzymatic methods were used to measure total cholesterol (CHOD-PAP cholesterol kit, Pars Azmun, Iran), LDL cholesterol (LDL-C kit, Pars Azmun, Iran), HDL cholesterol (CHOD-PAP cholesterol kit, Pars Azmun, Iran), and triglycerides (GPO-PAP triglycerides kit, Pars Azmun, Iran). Plasma insulin concentrations were determined by ELISA test (Monobind insulin microplate ELISA test, Monobind Inc., USA). Serum Mg levels was measured by colorimetric magnesium kit (Pars Azmun, Iran), and the following formula was used to measure insulin resistance:

\[ \text{HOMA-IR} = \frac{\text{FBG (mg/dl)} \times \text{FPI (mmol/L)}}{405} \]

**Statistical investigates**
The findings communicated as mean ± SD, and Kolmogorov-Smirnov test was used to check the normality of all variables.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo group (35)</th>
<th>Mg-treated group (35)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (F/M)</td>
<td>15/20</td>
<td>16/19</td>
<td>–</td>
</tr>
<tr>
<td>Age</td>
<td>40.65±12.74</td>
<td>40.73±11.9</td>
<td>0.64</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>28.92±0.19</td>
<td>28.81±0.15</td>
<td>0.34</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>165.37±7.46</td>
<td>163.22±7.67</td>
<td>0.63</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>140.02±6.59</td>
<td>143.2±5.8</td>
<td>0.21</td>
</tr>
<tr>
<td>LDL 9mg/dl</td>
<td>115.48±3.94</td>
<td>117.11±3.01</td>
<td>0.22</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>44.40±0.81</td>
<td>43.28±1.09</td>
<td>0.28</td>
</tr>
<tr>
<td>HDL/TG</td>
<td>0.28±0.01</td>
<td>0.28±0.01</td>
<td>0.39</td>
</tr>
<tr>
<td>Insulin (µU/ml)</td>
<td>6.67±0.76</td>
<td>6.66±0.08</td>
<td>0.98</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.53±0.03</td>
<td>1.49±0.02</td>
<td>0.39</td>
</tr>
<tr>
<td>FBS (mg/dl)</td>
<td>91.54±1.5</td>
<td>90.68±1.43</td>
<td>0.55</td>
</tr>
<tr>
<td>Mg (mg/dl)</td>
<td>1.93±0.02</td>
<td>1.98±0.03</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Table 1: Study variables in Mg treated and placebo group before intervention (data are expressed as mean±SD and comparisons between groups were analyzed using the Student’s t-test).

The possible changes between case and control group before intervention were analyzed by Student’s t-test. Comparisons between groups and the possible differences between means of each group during the intervention were conducted with repeated measure of ANOVA and analysis of covariance (ANCOVA). For the analyses, SPSS software, version 13, was used and P<0.05 accepted as statistically important.

**Results**
Seventy-six participants were included in this study, and unsystematically allocated to Mg-treated (n=38) and placebo (n=38) groups. In the Mg group, participants took 300 mg magnesium sulfate in form of herbal supplement capsules on a daily basis whereas in the placebo group, participants received placebo capsules. Three participants in each group were excluded during the follow-up period due to migration or failure to meet eligibility criteria. In all, thirty-five participants in Mg group and thirty-five in placebo group successfully completed the six-month intervention (Fig. 1). Study variables before and after the interventions are shown in Tables 1 and 2.

No statistical differences were seen between the two groups before intervention (Table 1). However, administration of herbal supplement containing 300 mg magnesium sulfate for 3 months significantly decreases plasma insulin level and HOMA-IR. Our results also showed that plasma HDL level significantly improved during the course of 3 months following Mg supplementation (Table 2).

The six-month Mg supplementation significantly increased plasma Mg level compared to placebo group, while plasma TG and LDL levels significantly decreased in the Mg-treated group (Table 2).

Our results also showed a significant decrease in plasma insulin level and HOMA-IR in the Mg-preserved group compared to the control group after six months of magnesium sulfate supplementation (Table 2). In Mg-treated group plasma HDL level and the HDL/TG ratio also significantly increased compared to the placebo group (Table 2).

**Discussion**
In this randomized double blind clinical trial in overweight participants, herbal supplement containing 300 mg Mg...
magnesium sulfate for six months significantly decreased plasma TG, LDL, Insulin levels and HOMA-IR, whereas a significant increase in plasma Mg level and HDL was witnessed.

It has been previously documented that oral MgSO₄ administration in streptozotocin (STZ) diabetic rat could decrease plasma glucose level via increasing GLUT4 gene expression in the muscles without any changes in insulin secretion (8). It seems that Mg can decrease insulin resistance and improve lipid profiles, thus based on our previous study in type 2 diabetic patients (13) and STZ-diabetic rats (8-12), this study was planned to determine whether oral herbal supplement containing MgSO₄ improves lipid profile, insulin resistance and insulin secretion in overweight non diabetic patients.

The results of the present study showed that plasma magnesium level increased six months after MgSO₄ therapy. Some controversy exists in the data in regard to the role of magnesium in insulin secretion. Few studies showed that, low serum magnesium concentration plays a role in hyperinsulinemia in non-diabetic individuals (4). Although it is believed that magnesium plays a role as a second messenger for insulin pathway and Mg⁺⁻ administration can decrease blood sugar after diabetes induction via insulin secretion and action, but the relationship between plasma magnesium level and glucose metabolism is independent of insulin secretion in diabetic patient (4). In our previous study, it was observed that MgSO₄ administration in type 2 diabetic patients for 3 months could not increase insulin secretion (13). It was also shown that oral MgSO₄ administration in STZ-diabetic rats for eight weeks did not increase insulin secretion (8) and glucose-stimulated insulin secretion is concentration-dependent in nature. However, in the presence of magnesium, insulin secretion did not show any changes (8). Our previous study supported the hypothesis that magnesium could decrease blood glucose via increase in GLUT4 mRNA expression, but not by increasing insulin secretion (8). GLUT4 is the main glucose carrier isoform in the insulin target tissues like adipose and skeletal muscle tissues and thus it is a very good index for insulin sensitivity (8). Our findings in the present study indicated that plasma insulin level and HOMA-IR (the index for insulin resistance) decreased after six months of Mg-therapy. This finding confirms our previous studies (8) and other studies as well (5, 6, 17-20). This data supports the idea that magnesium may play an important role in insulin sensitivity.

A meta-analysis of 9 randomized trials in diabetic patients reported that magnesium therapy of 4-16 weeks was effective in increasing HDL level but it had no effect on total cholesterol, LDL and triglyceride concentrations (21). Clinical data regarding the effect of Mg supplementation on serum lipids in diabetic patients conflict, are positive as several studies (5, 6, 17-20), such as Hadjistavri et al showed that oral magnesium supplementation 600 mg/day for 12 weeks in diabetic patients could decreases serum total cholesterol, LDL and triglyceride but it increases HDL level at the same time (13). On the other hand, other studies have reported zero or negative effects (22). Our previous studies in STZ-diabetic animal model (8-12) and type 2 diabetic patients (13) showed that oral MgSO₄ administration had a beneficial effect on some lipid profiles.

In the present study, it was shown that Mg supplementation associated with significant reductions in serum TG and LDL levels, parallel with a significant increase in HDL levels and HDL/TG ratio, whereas in the control group no effect on lipid profile was evident. These findings can be enlightened via the role of Mg in the lipoprotein lipase enzyme action (13). Mg deficiency improves catecholamine excretion which augmented lipolysis. Enhancement of lipolysis and subsequent elevation of plasma free fatty acids may lead to an increase in VLDL and TG synthesis and secretion and elevated plasma TG concentration (13).

The participants of the present study were volunteers and we also could not use euglycemic insulin clamp technique, a standard method for insulin secretion and resistance measurement, because it was very expensive and invasive for our patients. This was a limitation and weak point of this study.

Conclusion
From the results of the present study it can be concluded that herbal supplement containing MgSO₄ improves insulin sensitivity and has a beneficial effect on lipid-lowering

| Table 2. Study variables in Mg treated and placebo groups 3 months (M3) and 6 months (M6) after intervention and comparisons between groups were analyzed using the repeated measure and ANCOVA (data are expressed as mean ± SEM) |
|---------------------------------|--------|--------|--------|--------|--------|--------|--------|
|                                | M0     | M3     | M6     | M0     | M3     | M6     |
| Sex (F/M)                      | 15/20  | 15/20  | 15/20  | 16/19  | 16/19  | 16/19  |
| BMI                            | 28.92±0.19 | 28.92±0.19 | 28.92±0.19 | 28.81±0.15 | 28.81±0.15 | 28.81±0.15 |
| TG (mmol/L)                    | 165.37±7.46 | 159.21±6.92 | 163.17±6.1  | 163.22±7.67  | 159.11±6.67  | 141.2±5.84*  |
| Cholesterol (mg/dL)            | 140.02±6.59 | 142.8±4.3  | 139.45±5.28  | 143.2±5.8  | 137.65±5.1  | 131.3±4.27  |
| LDL (mg/dL)                    | 115.48±3.94 | 116.48±3.69 | 112.62±3.41  | 117.11±3.01  | 110.62±3.08  | 104.42±2.35*  |
| HDL (mg/dL)                    | 44.4±0.81  | 44.34±0.81  | 43.57±0.82  | 43.28±1.09  | 43.91±1.92  | 46±0.88*  |
| HDL/TG (mg/dL)                 | 0.28±0.01  | 0.29±0.01  | 0.27±0.01  | 0.28±0.01  | 0.29±0.01  | 0.34±0.01*  |
| Insulin (µU/mL)                | 6.67±0.76  | 6.71±0.11  | 6.41±0.11  | 6.66±0.08  | 6.27±1.01  | 5.83±0.06  |
| HOMA-IR (µU/mL)                | 1.5±0.03 | 1.52±0.03 | 1.37±0.05  | 1.49±0.02  | 1.36±0.03  | 1.22±0.02  |
| FBS (mg/dL)                    | 91.54±1.5  | 91.85±1.58 | 85.53±3.1  | 90.68±1.43  | 88.34±1.51  | 84.85±1.48  |
| Mg (µM)                        | 1.93±0.02 | 1.97±0.02 | 1.93±0.02  | 1.98±0.03  | 2.02±0.02  | 2.12±0.02  |

Abbreviation: Body mass index (BMI), Fasting blood glucose (FBG), Low density lipoprotein cholesterol (LDL), High density lipoprotein cholesterol (HDL), triglyceride (TG), magnesium (Mg), and HOMA-IR = FBG (mg/dL) × FPI (µU/mL) ÷ 405.
* Mg-treated-M3 vs Placebo-M3 and Mg-treated-M6 vs Placebo-M6 (p<0.0001)
# Mg-treated-M3 vs Placebo-M3 and Mg-treated-M6 vs Placebo-M6 (p<0.001)
$ Mg-treated-M3 vs Placebo-M3 and Mg-treated-M6 vs Placebo-M6 (p<0.05)
and it could be of great help for non-diabetic insulin resistance patients. The Mg deficiency plays an important role in insulin resistance and increased risk for type 2 diabetes and fatty liver in adults; hence Mg therapy is suggested as a low-cost, easy to use and natural component for prevention of type 2 diabetes.

Acknowledgments

This study was supported by Deputy of Research of Hormozgan University of Medical Sciences. We appreciate Niaq Pharmaceuticals Co for providing sincere medicine (Gorgan, I.R.Iran). All rights of the drug formulation reserved to Dr. Naghi Shahabi majd.

Conflict of Interests

The authors declare that they have no competing interests.

References


http://mjruiums.ac.ir
Med J Islam Repub Iran. 2019 (6 Feb); 33.2.